Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations

Departments of Epidemiology and Health Services Evaluation, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.
British Journal of Clinical Pharmacology (Impact Factor: 3.88). 12/2009; 68(6):956-62. DOI: 10.1111/j.1365-2125.2009.03544.x
Source: PubMed

ABSTRACT * Previous studies have suggested a tendency of antifolate drugs to be associated with higher rates of neural tube defects.
* This study makes use of the data on abortuses, which is missed in many other studies. In this case, the abortion data were critical. * The study documents that clinicians should avoid, as much as possible, the use of folic acid antagonists during the first trimester of pregnancy, when embryogenesis takes place.
To investigate the safety of folic acid antagonists during the first trimester of pregnancy in a large cohort.
Computerized databases for medications dispensed from 1998 to 2007 to women registered in 'Clalit' HMO, Israel southern district, was linked with maternal and infant hospitalization records, and to therapeutics abortions data. The risk for adverse pregnancy outcomes of folic acid antagonists exposure was assessed by adjusting for known confounders.
Eighty-four thousand, eight hundred and twenty-three infants were born and 998 therapeutic abortions took place; 571 fetuses and infants were exposed to one or more folic acid antagonists in the first trimester of pregnancy. Exposure was associated with an overall increased risk of congenital malformations [odds ratio (OR) 2.43, 95% confidence interval (CI) 1.92, 3.08], due mainly to increased risk for neural tube (adjusted OR 6.5, 95% CI 4.34, 9.15) and cardiovascular defects (OR 1.76, CI 1.05, 2.95).
First-trimester exposure to folic acid antagonists is associated with increased risk of congenital malformations.

Download full-text


Available from: Ilan Matok, Dec 25, 2013
20 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A clinical case of the development of therapeutic side effects in an epileptic woman of childbearing age is presented. The development of therapeutic side effects occurred on the background of an intermediate therapeutic dose of a valproic acid formulation and was associated with primary (idiopathic) and secondary (valproate-induced) impairments to the folate cycle on the background of a combination of a polymorphism in the CYP2C9*3 gene and a mutation in the MTHFR gene.
    Neuroscience and Behavioral Physiology 11/2012; 42(9). DOI:10.1007/s11055-012-9663-2
  • Academic Medicine 12/1964; 40(1):69. · 2.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The worldwide incidence of neural tube defects (NTDs) ranges from 1.0 to 10.0 per 1,000 births with almost equal frequencies between two major categories: anencephaly and spina bifida (SB). Epidemiological studies have provided valuable insight for (a) researchers to identify nongenetic and genetic factors contributing to etiology, (b) public health officials to design and implement policies to prevent NTD pregnancies, and (c) individuals to take precautions to reduce the chance of having an NTD-affected pregnancy. Despite extensive research, our knowledge of the genetic etiology of human NTDs is limited. Although more than 200 small animal models with NTDs exist, most of these models do not replicate the human disease phenotype. Over a hundred candidate genes have been examined for risk association to human SB. The candidate genes studied include those important in folic acid metabolism, glucose metabolism, retinoid metabolism, and apoptosis. Many genes that regulate transcription in early embryogenesis and maintain planar cell polarity have also been tested as candidates. Additionally, genes identified through mouse models of NTDs have been explored as candidates. We do not know how many genes in the human genome may confer risk for NTDs in human. Less than 20% of the studied candidate genes have been determined to confer even a minor effect on risk association. Many studies have provided conflicting conclusions due to limitations in study design that potentially affect the power of statistical analysis. Future directions such as genomewide association studies (GWAS) and whole exome or even whole genome sequencing are discussed as possible avenues to identify genes that affect risk for human NTDs.
    Developmental Disabilities Research Reviews 01/2010; 16(1):6-15. DOI:10.1002/ddrr.93 · 2.75 Impact Factor
Show more